4th November 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the develop
Glycostem announces initial clinical data to be presented at 2021 ASH Annual Meeting
Glycostem donates funding to the Acute Leukemia Advocates Network and Leukaemia Care
11th May 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, announced the donation to the Acute Leukemia Advocates Network (ALAN) and to Leukaemia Care.
Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments
12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf
Glycostem and Ghent University sign license agreement on NK cell therapy technology
17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn
Glycostem announces treatment of first patient in pivotal phase I/IIa trial
15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for th
Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia
20th November 2020 – Glycostem today announced the
FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
Glycostem collaborates with LUMICKS
30th July, 2020 - LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development.
Glycostem enters contract with Autolomous to digitise manufacturing process
3rd June, 2020 – Autolomous Ltd, a leading edge developer of innovative digital solutions for manufacture of advanced medicines, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today a